Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease
Pediatric Pulmonology · 2023-08 · 58 (8) · 2317-2322
DOI: 10.1002/ppul.26486 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Pediatric Pulmonology, online erschienen am 24.05.2023. Verfasst von Bente L Aalbers und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
A triple combination of CFTR modulators ELE/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor, Trikafta™) has been evaluated in clinical trials for people with cystic fibrosis (pwCF) and was approved to the European and US market. During registration and settling reimbursement in Europe, it could be requested on a compassionate use basis, for patients with advanced lung disease (ppFEV 1 < 40).
Aim
The aim of this study is to evaluate 2 years of experience with the clinical and radiological response of ELE/TEZ/IVA in pwCF in a compassionate use setting. Methods pwCF who started ELE/TEZ/IVA in a compassionate use setting were prospectively followed with assessment of spirometry, BMI, chest CT, CFQ‐R and sweat chloride concentration (SCC) before start and after 3 months. Furthermore, spirometry, sputum cultures, and BMI were repeated after 1, 6, 12, 18, and 24 months.
Results
Eighteen patients were eligible for this evaluation, nine with F508del/F508del genotype (eight of whom were using dual CFTR modulators) and nine with F508del/minimal function mutation. After 3 months, mean change in SCC was −44.9 ( p ≤ 0.001), together with significant improvement in CT (change in Brody score: −28.27 p ≤ 0.001) and CFQ‐R results (change in respiratory domain: +18.8, p = 0.002). After 24 months, ppFEV 1 change was +8.89 ( p = 0.002), BMI had improved by +1.53 kg/m 2 ( p ≤ 0.001) and exacerbation rate declined from 5.94 in 24 months before start to 1.17 ( p ≤ 0.001) in the 24 months after. Conclusion pwCF with advanced lung disease experience relevant clinical benefit after 2 years of treatment with ELE/TEZ/IVA in a compassionate use setting. Structural lung damage, quality of life, exacerbation rate, and BMI improved significantly with treatment. Gain in ppFEV 1 is lower compared to the phase III trials that included younger patients with moderately affected lung function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
- Department of Radiology, UMC Utrecht, Utrecht University, Utrech, The Netherlands.
- Department of Pediatric pulmonology, UMC Utrecht location Wilhelmina Childrens Hospital, Utrecht University, Utrech, The Netherlands.
ORCID-Profile: Bente L Aalbers
Zitieren
APA
Aalbers, B. L., Mohamed Hoesein, F. A. A., Hofland, R. W., Bronsveld, I., Kruijswijk, M. A., Schotman, S., Slingerland, C. W., Panhuis, H., van der Ent, C. K., & Heijerman, H. G. M. (2023). Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease. Pediatric Pulmonology, 58(8), 2317-2322. https://doi.org/10.1002/ppul.26486
Vancouver
Aalbers BL, Mohamed Hoesein FAA, Hofland RW, Bronsveld I, Kruijswijk MA, Schotman S, et al. Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease. Pediatric Pulmonology. 2023;58(8):2317-2322. doi:10.1002/ppul.26486
BibTeX
@article{Aalbers2023,
author = {Aalbers, Bente L and Mohamed Hoesein, Firdaus A A and Hofland, Regina W and Bronsveld, Inez and Kruijswijk, Marian A and Schotman, Suzan and Slingerland, Corlien W and Panhuis, Hannah and van der Ent, C Kors and Heijerman, Harry G M},
title = {Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease},
journal = {Pediatric Pulmonology},
year = {2023},
volume = {58},
number = {8},
pages = {2317--2322},
doi = {10.1002/ppul.26486}
}
EUVIMED